Tekmira Pharmaceuticals

Tekmira changes name to Arbutus Biopharma, a hepatitis B solutions company

Wednesday, July 22, 2015

Tekmira Pharmaceuticals, headquartered in Vancouver, Canada, plans to change its corporate name to Arbutus Biopharma, a therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), to be effective on or before Aug. 3. The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the singular goal of delivering a cure for chronic HBV. The combined entity currently fields a large portfolio of HBV product candidates in the industry.

[Read More]

FDA modifies partial clinical hold on Tekmira’s TKM-Ebola IND

Thursday, April 16, 2015

The FDA has notified Tekmira Pharmaceuticals, a therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV) headquartered in Vancouver, BC, Canada, that the partial clinical hold on the company’s Investigational New Drug application (IND) for TKM-Ebola has been modified to permit repeat dosing of healthy volunteers at a dose of 0.24mg/kg/day. The IND remains on partial clinical hold with regard to doses above 0.24mg/kg/day in healthy volunteers.

[Read More]

Tekmira Pharmaceuticals, OnCore Biopharma to merge

Wednesday, January 14, 2015

Tekmira Pharmaceuticals, based in Vancouver, a developer of RNA interference (RNAi) therapeutics, and OnCore Biopharma, a Doylestown, Pa.-based biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, have agreed to merge to create a new global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.

[Read More]

Profectus BioSciences receives Army funding for Ebola, Marburg viruses

Thursday, October 23, 2014

Profectus BioSciences, a Baltimore, Md.-based clinical-stage vaccine company, and the Galveston National Laboratory (GNL) at the University of Texas Medical Branch at Galveston (UTMB) have received a three-year $8.5 million grant from the U.S. Army. The grant will support studies directed at early steps of the ongoing development of a vaccine to provide pre- and post-exposure protection against exposure with all major strains of Ebola and Marburg viruses.

[Read More]